Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health care giant Abbott Laboratories (NYSE:ABT) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Abbott and see what CAPS investors are saying about the stock right now.

Abbott facts

Headquarters (founded)

Abbott Park, Ill. (1888)

Market Cap

$58.9 billion

Industry

Health care equipment

Trailing-12-Month Revenue

$40 billion

Management

Chairman/CEO Miles White (since 1999)
CFO Thomas Freyman (since 2001)

Return on Equity (average, past 3 years)

20.6%

Cash / Debt

$8.5 billion / $7.1 billion

Dividend Yield

1.5%

Competitors

Boston Scientific
Johnson & Johnson
Mead Johnson Nutrition

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 97% of the 2,617 members who have rated Abbott believe the stock will outperform the S&P 500 going forward.

Just last week, one of those Fools, cschweit, succinctly summed up the Abbott bull case for our community:

Undervalued stock as of right now. Biggest growth will come from emerging markets. Will need to deliver to those emerging markets if it will succeed -- which I think it can. A little worried about a major buyout of its major branches. ... Still a strong company with a good future.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.